SELLAS Life Sciences (SLS) Common Equity (2010 - 2026)
SELLAS Life Sciences (SLS) recorded Common Equity of $137.66 million in Q2 2026, up 426.4% from $26.15 million a year earlier and up 28.2% from the prior quarter.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025, SELLAS Life Sciences reported Common Equity of $70.87 million, up 648.8% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of 20.4% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $9.47 million in FY2024, -$7.98 million in FY2023, $4.85 million in FY2022 (-76.2%) and $20.35 million in FY2021 (-27.2%).
- The Q2 2026 figure is the highest quarterly Common Equity in data going back to Q4 2010.
- On a year-over-year basis, Common Equity has increased for six consecutive quarters, with growth averaging 422.3% over the last six quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 797.7% in Q2 2025, against a decline of 86.0% in Q1 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $107.41 million (Q1 2026), $70.87 million (Q4 2025) and $45.63 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | SELLAS Life Sciences | 2.34 Bn | 2.34 Bn | - | 137.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 137.66 Mn |
| Mar 31, 2026 | 107.41 Mn |
| Dec 31, 2025 | 70.87 Mn |
| Sep 30, 2025 | 45.63 Mn |
| Jun 30, 2025 | 26.15 Mn |
| Mar 31, 2025 | 27.76 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 15.89 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | -7.98 Mn |
| Sep 30, 2023 | -3.83 Mn |
| Jun 30, 2023 | 4.84 Mn |
| Mar 31, 2023 | 13.17 Mn |
| Dec 31, 2022 | 4.85 Mn |
| Sep 30, 2022 | 12.60 Mn |
| Jun 30, 2022 | 19.06 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 20.35 Mn |
| Sep 30, 2021 | 26.61 Mn |
API Access
SELLAS Life Sciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=SLS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "SLS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=SLS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();